Skip to main content
Fig. 4 | Experimental Hematology & Oncology

Fig. 4

From: Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma

Fig. 4

Co-treatment with carfilzomib and CUDC-907 induces cytotoxicity in the myeloma cells. ac The myeloma cells were treated with carfilzomib and/or CUDC-907 for 48 h or 72 h. Caspase 3/7 activity (a), apoptotic cells (b), and cytotoxicity (c) were analyzed. *P < 0.05 compared to carfilzomib and CUDC-907 co-treated cells. d Myeloma cells were treated with carfilzomib and/or CUDC-907 for 48 h. Mitochondrial membrane potential was determined using the Mitochondria Staining Kit. *P < 0.05 compared to carfilzomib and CUDC-907 co-treated cells. e Cells were incubated with carfilzomib and/or CUDC-907 for 72 h. Intracellular ATP levels were determined using the ‘Cell’ ATP assay reagent Ver. 2 kit. *P < 0.05 vs. carfilzomib and CUDC-907 co-treatment groups. f Myeloma cells were treated with the indicated concentrations of carfilzomib and/or CUDC-907 for 24 h. Total cell lysates were evaluated by immunoblotting. g, h Myeloma cells were treated with the indicated concentrations of CUDC-907 for 72 h. The effect of CUDC-907 treatment on cellular growth (g) and cytotoxicity (h) was evaluated. *P < 0.05 compared to carfilzomib and CUDC-907 co-treated cells. Results represent the mean of three independent experiments

Back to article page